Berleze, K. J., Ferreira, L. F., D’Ávila, A. F., Buss, C., Tovo, & Telles Da Rosa, L. H. (n.d.). Impacts and prevalence of sarcopenia in patients with MASLD: a Cross-Sectional study. Journal of Clinical Research & Bioethics, 14(S17). https://www.walshmedicalmedia.com/open-access/impacts-and-prevalence-of-sarcopenia-in-patients--with-masld-a-crosssectional-study.pdf
Berleze, K. J., Ferreira, L. F., D’Ávila, A. F., Buss, C., Tovo, & Telles Da Rosa, L. H. (n.d.). Impacts and prevalence of sarcopenia in patients with MASLD: a Cross-Sectional study. Journal of Clinical Research & Bioethics, 14(S17). https://www.walshmedicalmedia.com/open-access/impacts-and-prevalence-of-sarcopenia-in-patients--with-masld-a-crosssectional-study.pdf
Berleze, K. J., Ferreira, L. F., D’Ávila, A. F., Buss, C., Tovo, & Telles Da Rosa, L. H. (n.d.). Impacts and prevalence of sarcopenia in patients with MASLD: a Cross-Sectional study. Journal of Clinical Research & Bioethics, 14(S17). https://www.walshmedicalmedia.com/open-access/impacts-and-prevalence-of-sarcopenia-in-patients--with-masld-a-crosssectional-study.pdf
Berleze, K. J., Ferreira, L. F., D’Ávila, A. F., Buss, C., Tovo, & Telles Da Rosa, L. H. (n.d.). Impacts and prevalence of sarcopenia in patients with MASLD: a Cross-Sectional study. Journal of Clinical Research & Bioethics, 14(S17). https://www.walshmedicalmedia.com/open-access/impacts-and-prevalence-of-sarcopenia-in-patients--with-masld-a-crosssectional-study.pdf
Abstract
Introduction: Sarcopenia, muscle loss, often coexists with MASLD, a common liver disorder, which is more prevalent in those with sarcopenia. Sarcopenia also increases the risk of liver conditions like steatosis and fibrosis. Studies on sarcopenia in MASLD are common in developed countries, but fewer follow the EWGSOP2 guidelines in Brazil. Aim: to assess sarcopenia prevalence in MASLD patients. Methods: Cross-sectional study conducted at the Gastroen-terology/Hepatology Service of ISCMPA with patients diagnosed with MASLD. The EWGSOP2 criteria were used to evaluate sarcopenia. Categorical data presented as absolute and relative frequency; parametric continuous data ex-pressed as mean±standard deviation; non-parametric continuous data as me-dian and IQR. Gender differences in were analyzed using Fisher's Exact Test or Chi-squared tests, and for continuous variables, T Student tests (parametric) and Mann-Whitney U tests for independent samples (non-parametric). The significance level was set at 5% (p<0.05). Results: The study involved 103 MASLD patients with an average age of 60.39 years, comprising 48 (46.60%) adults and 55 (53.40%) older individuals. Concerning sarcopenia diagnosis, four individuals exhibited decreased muscle strength; two had reduced MME (sarcopenia); and one showed decreased walking speed (severe sarcopenia). Among the participants, 63 (60.6%) were physically active. 35 (62.5%) had mild to moderate steatosis, while 21 (37.5%) had severe steatosis. In terms of EHNA, 13 subjects (24.08%) had moderate to severe EHNA. Regarding fibrosis classi-fication, 68 (72.34%) individuals had undetermined or high probability based on the NAFLD score, with higher prevalence in males (n=23; 88.5%). Fibrosis assessment via liver biopsy revealed 27 (28.72%) in F1 and F2 and 15 (16.96%) in F3 and F4. Stratification of fibrosis into F3 and F4 was more com-mon among men (n=9; 47.4%). Conclusion: Most of the population was physi-cally active. The parameters indicating sarcopenia exceeded the thresholds recommended by EWGSOP2. The prevalence of sarcopenia was low in individuals with MASLD.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
